Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered...
DeepSeek’s AI: Transforming Drug Development and Healthcare in China
DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the...
MediLink Therapeutics’ YL217 Receives FDA IND Clearance for Novel ADC Targeting Gastrointestinal Cancers
MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC),...
AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with...
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co.,...
Roche Reports 7% Revenue Growth in 2024, Driven by Oncology and Ophthalmology
Roche (SWX: ROG) released its 2024 annual financial report on January 30, showing a 7%...
DeepSeek Enhances Biopharma IND and NDA Processes with AI
In the regulatory submissions for Investigational New Drug (IND) and New Drug Application (NDA) in...
Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) jointly announced that their co-developed antibody-drug...
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...
CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America
CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development,...
MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...
MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...
FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...
Jiangsu Yuyue Partners with Inogen for International Distribution and R&D
China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership...
Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced...
MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study
Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...
NHSA Targets Low-Volume Drugs in National Reimbursement List
The National Healthcare Security Administration (NHSA) in China has released a list of 131 drugs...
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...
GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...